Sentences with phrase «effect of each drug on»

Exclusive or comfort breastfeeding: The amount of breastmilk your baby receives will also contribute to the effect of the drug on your baby.

This can guide drug discovery by letting you simulate the effect of a drug on the circuit.

If you study the effects of drugs on mice, you should append actual mice to your manuscript.

While the individual effects of the drugs on virus - specific CTL differ somewhat depending on specific assays, schedules, and doses, treatment with any of the three HDAC inhibitors impaired the ability of CTL to kill HIV - infected immune cells.

First, the study is based on data from only six states where this information is captured; secondly, the effects of drugs on driving performance and crash risk vary by drug type, dosage, and the driver's physiological response and tolerance level.

One of the most immediate effects of drugs on the brain is an increase in the levels of dopamine, particularly in a region of the brain called the nucleus accumbens.

Researchers were particularly interested in studying the effects of the drug on young mice, which are still growing new bone and have much lower levels of sclerostin.

In Britain, controversy has surrounded the effects of the drug on the liver.

BTMs can reflect the early effect of the drug on bone tissue.

New insights about the brain are changing the way the law handles cases related to adolescent decision making, the effects of drugs on the brain, memory and lie detection, and states of consciousness, among others.

Simon's strategy is to compare the effects of a drug on a normal strain of yeast and a strain with a mutation in one of the many genes that affect normal cell division - a property that is disrupted in cancerous cells.

The purpose of this study is to determine the effects of these drugs on the inflow and outflow of fluid from the eye and its consequences on eye pressure.

Vanderbilt neuroscience was built in part by psychopharmacologists who helped define — at the molecular level — the effects of drugs on the brain and nervous system.

Replacing animal testing, it can accurately replicate human - organ interactions for weeks at a time and can allow for measuring the effects of drugs on different parts of the body, according to the engineers.

The results don't indicate whether one causes the other, but they do show that connectivity patterns could one day help predict traits or offer broad indicators of the effect of drugs on the brain.

The effects of the drug on testosterone levels appear varied.

My aim with the diet is to limit the side effects of the chemo and enhance the effects of the drugs on my tumour whilst they are in my body.

Find videos, games, blog posts, that explore the effects of drugs on the brain and body.

This desire sharply manifests itself when the effect of the drug on the body ends.

Cardiovascular pharmacology: This branch of pharmacology deals with the study of the effects of drugs on the human's cardiovascular system, including the heart and blood vessels.

According to the Bureau of Labor Statistics, both pharmacologists and zoologists study the effects of drugs on animals.

However, the effects of these drugs on a cat's thyroid hormone levels would probably be similar and, if a cat was receiving any of them, it might muddy the waters or one might misjudge the seriousness of a case of feline hyperthyroidism.

If your veterinarian has prescribed Prednisone for your dog, you may want to consider the following options to try to reduce the negative side - effects of the drug on your dog:

Bethesda, MD About Blog Find timely topics, written for teens, that apply the science of drug use to real life - the effects of drugs on the teen's brain, body, and life.

Shedding light on an often misunderstood force in history, author Peter Watts waded through the whole collection and created Altered States — an unprecedented insight into the effect of drugs on life, politics and popular culture.

A DRE is a police officer who has specialized training in the effects of drugs on individuals.

While the specific effect of each drug on your body takes place in differing stages, the effect of drivers operating a vehicle while under the influence is disastrous.

RED Driving School CEO Ian McIntosh says: «It is shocking that so many UK drivers have admitted to driving on drugs and this shows a worrying level of complacency by drivers about the effects of drugs on their driving.

The degree also helps me in my postgraduate course because I can now understand the effects of drugs on patients in real life and apply my knowledge to real - world situations.

Bethesda, MD About Blog Find timely topics, written for teens, that apply the science of drug use to real life - the effects of drugs on the teen's brain, body, and life.

Find videos, games, blog posts, that explore the effects of drugs on the brain and body.

Find videos, games, blog posts, that explore the effects of drugs on the brain and body.

Parents say they talk about the effects of drugs on the teenage brain.

Not exact matches

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

Earlier this year Merck halted trials on its once - promising Alzheimer's drug after an independent panel of ruled there was «virtually no chance of finding a positive clinical effect.»

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

«Hitler was not insane or deranged, or suffering from drug - induced delusions,» he writes, «or laboring under the effects of some chronic disease such as syphilis, or acting in an unresolved hypnotic trance: on the contrary, he was sane according to any reasonable definition of the term, and fully responsible for his actions.»

Shaked said Israeli authorities would now put their focus on education about the possible harmful effects of drug use.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In an editorial accompanying the new study, Dr. Wilson Compton of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effects.

These healthcare brands will have the effect of soothing out the inevitable fluctuations that occur on the pharmaceutical side, though right now, Glaxo's portfolio is boasting robust growth from small - scale HIV drugs Triumeq and Trivicay (which, as the CEO noted in the last annual report, sport year - over-year sales growth of 41 % and 43 %, respectively).

The effect of substitutes is dependent on the individual drug.

The charges suggest that a small group of health - care firms — ones that acquire the rights to drugs and significantly increase their prices — is drawing the scrutiny of regulators and prosecutors, with a possible chilling effect on aggressive drug - pricing strategies.

According to Living Goods, clients may also be reluctant to buy drugs from other private providers because of the risk of getting a counterfeit medicine.63 Living Goods sent us a study conducted at the midline of its RCT that claims that both availability of counterfeit drugs and drug prices decreased at private retailers in areas where CHPs worked.64 According to the study, about 37 % of private drug shops in the areas it studied sold fake ACT drugs, 65 and availabilty of fake ACTs was about 50 % lower among non-Living Goods sellers in the areas where Living Goods worked.66 Additional results on these potential effects will be made available when the full RCT is published.

Martin Shkreli, the founder and chief executive of Turing, said that the drug is so rarely used that the impact on the health system would be minuscule and that Turing would use the money it earns to develop better treatments for toxoplasmosis, with fewer side effects.

Every year the FDA monitors the testing of 3,000 new drugs on nearly 200 million people to determine their effects.

Nevertheless, prescription drugs CPI is only 1.37 % of the aggregate index (according to a BLS official at the time of writing), thus the overall effect on medical care inflation and headline aggregate index should be limited.

Perhaps so many of these new drugs fail to have an effect because the basic research on which their development was based isn't valid.

There is enough evidence that antidepressants cause increased risk of suicide and violence for the U.S. Food and Drug Administration and its Canadian counterpart to require that drug companies include a «black box» warning to that effect on their packaDrug Administration and its Canadian counterpart to require that drug companies include a «black box» warning to that effect on their packadrug companies include a «black box» warning to that effect on their packages.

For instance, it is remarkable how little attention is given to the effects of alcohol, drugs, and tranquilizers on the lives of church members.